Edition:
United States

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

2.91USD
18 Jan 2019
Change (% chg)

$-0.19 (-6.13%)
Prev Close
$3.10
Open
$3.08
Day's High
$3.08
Day's Low
$2.88
Volume
50,762
Avg. Vol
199,596
52-wk High
$58.50
52-wk Low
$1.70

Latest Key Developments (Source: Significant Developments)

Altimmune Q3 Revenue $2.6 Million Versus $4.6 Million
Tuesday, 13 Nov 2018 04:49pm EST 

Nov 13 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 REVENUE $2.6 MILLION VERSUS $4.6 MILLION.QTRLY LOSS PER SHARE $1.73.  Full Article

Altimmune Says Board Approved One-For-Thirty Reverse Stock Split Of Co's Shares
Wednesday, 12 Sep 2018 05:59pm EDT 

Sept 12 (Reuters) - Altimmune Inc ::ALTIMMUNE - ON SEPT 7, BOARD APPROVED IMPLEMENTATION OF A ONE-FOR-THIRTY (1:30) REVERSE STOCK SPLIT OF CO'S SHARES- SEC FILING.ALTIMMUNE INC - CO'S CONSOLIDATED COMMON STOCK WILL BEGIN TRADING ON NASDAQ GLOBAL MARKET ON A SPLIT-ADJUSTED BASIS ON SEPT 14.  Full Article

Altimmune Files To Say Offering About 58 Mln Common Units
Friday, 17 Aug 2018 05:31pm EDT 

Aug 17 (Reuters) - Altimmune Inc ::ALTIMMUNE FILES TO SAY OFFERING ABOUT 58 MILLION COMMON UNITS, EACH UNIT MADE OF 1 SHARE OF COMMON STOCK & A WARRANT TO PURCHASE 1 SHARE OF COMMON STOCK.  Full Article

Altimmune Announces Financial Results For Year Ended Dec 31
Wednesday, 28 Mar 2018 04:44pm EDT 

March 28 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2017 AND PROVIDES CORPORATE UPDATE.ALTIMMUNE - AT DECEMBER 31, 2017, HAD CASH, CASH EQUIVALENTS, AND RESTRICTED CASH OF APPROXIMATELY $12.3 MILLION.  Full Article

Hudson Bay Capital Management Reports A 9.99 Percent Passive Stake In Altimmune
Friday, 2 Feb 2018 01:25pm EST 

Feb 2 (Reuters) - Hudson Bay Capital Management LP ::HUDSON BAY CAPITAL MANAGEMENT LP‍ REPORTS A 9.99 PERCENT PASSIVE STAKE IN ALTIMMUNE, INC​ AS OF DECEMBER 31, 2017 - SEC FILING.  Full Article

Altimmune Elects Mitchel Sayare As Chairman Of Its Board
Wednesday, 3 Jan 2018 08:00am EST 

Jan 3 (Reuters) - Altimmune Inc ::ALTIMMUNE ELECTS MITCHEL SAYARE, PH.D. AS CHAIRMAN OF ITS BOARD OF DIRECTORS.ALTIMMUNE INC - BOARD'S CURRENT CHAIRMAN, DAVID DRUTZ WILL REMAIN ON AS CHAIRMAN OF COMPENSATION COMMITTEE AND MEMBER OF BOARD.  Full Article

Altimmune reports Q3 loss per share $2.05
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Altimmune Inc :Altimmune announces third quarter 2017 financial results and provides corporate update.Q3 loss per share $2.05.Q3 preliminary loss per share $0.34 excluding items.Altimmune Inc qtrly revenue and grants and contracts were $4.6 million versus $0.9 million​.Altimmune Inc - ‍at september 30, 2017, company had cash and cash equivalents of approximately $17.1 million​.Altimmune Inc - ‍initiated a phase 2 clinical trial with nasovax vaccine with initial data expected in q1 2018​.  Full Article

Altimmune submits investigational new drug application for Nasovax for phase 2 trial preparation
Monday, 21 Aug 2017 08:00am EDT 

Aug 21 (Reuters) - Altimmune Inc :Altimmune submits investigational new drug application for Nasovax in preparation for Phase 2 trial.Previous versions of Nasovax evaluated in two phase 1 studies under earlier inds were immunogenic and well tolerated.Phase 2 data is expected sometime in Q1 of 2018.  Full Article

Altimmune announces $14.7 million Series B preferred stock offering
Thursday, 17 Aug 2017 08:00am EDT 

Aug 17 (Reuters) - Altimmune Inc :Altimmune announces $14.7 million Series B preferred stock offering.Altimmune - To use net proceeds from this financing for continued advancement of development activities for company's clinical-stage product pipeline​.  Full Article

Altimmune posts Q2 loss of $0.26 per share
Thursday, 10 Aug 2017 12:24am EDT 

Aug 10 (Reuters) - Altimmune Inc :Altimmune announces second quarter 2017 financial results and provides corporate update.Remains on track to initiate Phase 2 trial in Nasovax in Q3.Altimmune Inc - expect to have sufficient resources to fund our current and planned development programs through key clinical milestones and 2Q 2018.Qtrly net loss per share $0.26.Altimmune - Quaterly revenue and grants and contracts were $3.0 million and $3.3 million, respectively, compared to $0.8 million and $1.3 million.  Full Article